Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

Inclusion Criteria

• •Diagnosis of ileal, ileo-colonic, or colonic Crohn's Disease (CD) for \> 3 months prior to screening
• •Men or women age 18 - 80 years at the time of screening
• •Moderate to severely active CD, as defined by Crohn's Disease Activity Index (CDAI) and endoscopic demonstration of inflammation
• •Stable dose of medications for Crohn's disease therapy
• •Prior treatment failure or intolerance with at least one Anti-Tumor Necrosis Factor-Alpha Therapy (anti-TNF α) agent
• •Effective contraception from screening, and for 36 weeks after the last dose of investigational product
• •No known history of active tuberculosis (TB) \& negative assessment for TB/latent TB